Proteomics And Bioinformatics Analyses Of Exosomes And Secretome For The Detection Of Colorectal Cancer Biomarkers
Funder
National Health and Medical Research Council
Funding Amount
$290,032.00
Summary
Cancer of colon and rectum is the most common form of cancer in Australia with 12,000 people diagnosed each year. Of these, more than 4,000 people will die of their disease. Early detection of colorectal cancer (CRC) will significantly improve the patient outcomes and will reduce the human and financial burden this disease places on the community. This research project aim to discover new ways to detect CRC and develop blood-based assays. Validation of these assays will be performed in clinical ....Cancer of colon and rectum is the most common form of cancer in Australia with 12,000 people diagnosed each year. Of these, more than 4,000 people will die of their disease. Early detection of colorectal cancer (CRC) will significantly improve the patient outcomes and will reduce the human and financial burden this disease places on the community. This research project aim to discover new ways to detect CRC and develop blood-based assays. Validation of these assays will be performed in clinical studies using CRC patient samples.Read moreRead less
Companion Biomarker And Therapeutic Strategy Development For Pancreatic Cancer
Funder
National Health and Medical Research Council
Funding Amount
$121,031.00
Summary
Innovation of predictive and responsive biomarkers in pancreatic cancer (PC) is of paramount importance. This project contains two parts: 1. Circulating DNA. It has been shown previously that DNA released into the blood stream by cancer can be measured, its usefulness in PC will be assessed. 2. ROCK-I as a predictive biomarker. ROCK-I is a protein involved in cell motility. The ability for ROCK-I amplification to predict for response to ROCK-I inhibitors will be assessed in vitro/in vivo.
Novel Therapeutic Strategies For Pancreatic Cancer Using Next Generation Sequencing
Funder
National Health and Medical Research Council
Funding Amount
$354,892.00
Summary
Dr David Chang is a surgeon scientist who specialises in the treatment of pancreatic cancer. His research focus is on the development and implementation of novel therapeutic strategies for pancreatic cancer. He aims to achieve this by utilising novel biomarkers that have the ability to forecast prognosis and response to treatments. Ultimately, this will lead to the “individualised” treatment for each patient.
An In Vitro Pipeline For Liquid Biopsy Biomarkers For Cancer Diagnosis And Therapy
Funder
National Health and Medical Research Council
Funding Amount
$3,764,215.00
Summary
A droplet of blood contains information whether a person has cancer, the stage of the cancer and how their response to treatment. The proposed research will employ ultrasensitive detection technologies to analyse so-called biomarkers released from cancer cells. We will use lab-based models of cancer, generated with a 3D bioprinter, to learn what biomarkers tell us about cancer type and response to drugs. This knowledge is urgently needed for early cancer detection and better cancer treatment.
Bowel cancer is the 2nd most common cause of cancer death in Australia. Rectal cancer represents 40% of these, and is more common in the elderly who are frequently unable to tolerate chemoradiation therapy. The Mutated in Colorectal Cancer gene (MCC) could become a predictor to chemoradiotherapy in up to 30% of these patients. A defective MCC in tumours can predict a good response to this treatment. Our project will potentially identify patients that are more sensitive to chemoradiotherapy and l ....Bowel cancer is the 2nd most common cause of cancer death in Australia. Rectal cancer represents 40% of these, and is more common in the elderly who are frequently unable to tolerate chemoradiation therapy. The Mutated in Colorectal Cancer gene (MCC) could become a predictor to chemoradiotherapy in up to 30% of these patients. A defective MCC in tumours can predict a good response to this treatment. Our project will potentially identify patients that are more sensitive to chemoradiotherapy and lead to a personalized treatment of rectal cancer.Read moreRead less
Strategies For Enhancing The Treatment Of Colon Cancer.
Funder
National Health and Medical Research Council
Funding Amount
$590,785.00
Summary
Colorectal cancer is the third leading cause of cancer related death in Australia. Strategies to improve outcomes for these patients are urgently needed. This NHMRC SRF Fellowship will seek to identify new molecules in cancer cells which can be targeted to treat this disease, and to discover genes which can be used to improve patient response to treatment.
Combining PI3K, CDK4/6 Pathway Inhibitors And Immunotherapies In Triple-negative Breast Cancer (TNBC): A Novel Therapy Combination
Funder
National Health and Medical Research Council
Funding Amount
$626,345.00
Summary
Triple-negative breast cancer (TNBC) has the worst prognosis of all breast cancer subtypes, classically affecting young women and characterized by a lack of effective therapies. We show that blocking both PI3K and CDK4/6 pathways together effectively reduces TNBC growth in mice and can enhance anti-tumour immune responses. We aim to understand how these drugs work together and if adding immunotherapy can improve responses. Our project could provide a new treatment approach for TNBC patients.
Epigenetic Changes In The Prostate Cancer Microenvironment
Funder
National Health and Medical Research Council
Funding Amount
$848,954.00
Summary
Many men with prostate cancer have slow-growing tumours that are unlikely to spread outside the prostate. These men with low-risk cancer are often monitored to prevent unnecessary aggressive treatments. However, the current methods used to distinguish between slow-growing and aggressive tumours are imprecise and there is a risk of missing aggressive tumours. We aim to identify new biomarkers of prostate cancer by measuring modifications to the DNA in the tumour and surrounding cells
Role Of Proline-rich Tyrosine Kinase 2 (Pyk2) In Ovarian Cancer
Funder
National Health and Medical Research Council
Funding Amount
$85,254.00
Summary
Ovarian cancer is one of the most lethal gynaecological cancers in the developed world. Elevated levels of gonadotropin hormones and cell protein Pyk2 have been implicated in ovarian cancer. Our aim is to determine the role of Pyk2 in growth and metastasis of ovarian cancer when stimulated with gonadotropins. In addition, we aim to identify protein changes which occur in ovarian cancer when stimulated by gonadotropins in order to identify new biomarkers for the disease.